Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

@article{Stackelberg2016PhaseII,
  title={Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.},
  author={A. von Stackelberg and F. Locatelli and G. Zugmaier and R. Handgretinger and T. Trippett and C. Rizzari and P. Bader and M. O'Brien and Beno{\^i}t Brethon and D. Bhojwani and P. Schlegel and A. Borkhardt and S. Rheingold and T. Cooper and C. Zwaan and P. Barnette and C. Messina and G. Michel and S. DuBois and Kuolung Hu and Min Zhu and J. Whitlock and Lia Gore},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 36},
  pages={
          4381-4389
        }
}
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled children < 18 years old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, using 6-week treatment cycles… Expand
257 Citations

Paper Mentions

Interventional Clinical Trial
This study combines the immune checkpoint inhibitor pembrolizumab with the BITE antibody blinatumomab for the treatment of relapsed/refractory pre-B cell ALL. Pembrolizumab at the… Expand
ConditionsLeukemia, B-cell, Lymphoma, B-Cell
InterventionDrug
A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
  • Highly Influenced
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
  • 16
  • Highly Influenced
  • PDF
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
  • 1,408
Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
  • 10
  • PDF
Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
  • 19
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
...
1
2
3
4
...